BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21373647)

  • 21. Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers.
    Hill BT
    Curr Pharm Des; 2001 Sep; 7(13):1199-212. PubMed ID: 11472262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vinflunine in Advanced Transitional Cell Cancer of the Urothelial Tract: A Potential Option for Maintenance Therapy? A Case Series.
    Palumbo R; Licata L; Sottotetti F; Tagliaferri B; Pozzi E; Teragni C; Quaquarini E; Bernardo A
    Oncol Res Treat; 2018; 41(1-2):8-13. PubMed ID: 29402855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
    Jordan MA; Horwitz SB; Lobert S; Correia JJ
    Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.
    Castellano D; Puente J; de Velasco G; Chirivella I; López-Criado P; Mohedano N; Fernández O; García-Carbonero I; González MB; Grande E
    BMC Cancer; 2014 Oct; 14():779. PubMed ID: 25342282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
    Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
    Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Care of advanced or metastatic bladder cancer in second line: A specific place for vinflunine].
    Houédé N; Milano G
    Bull Cancer; 2019 May; 106(5):431-435. PubMed ID: 30981463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vinflunine in the treatment of bladder cancer.
    Bachner M; De Santis M
    Ther Clin Risk Manag; 2008 Dec; 4(6):1243-53. PubMed ID: 19337431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial.
    Shah CH; Pappot H; Agerbæk M; Holmsten K; Jäderling F; Yachnin J; Grybäck P; von der Maase H; Ullén A
    Oncologist; 2019 Jun; 24(6):745-e213. PubMed ID: 30552156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland.
    Hussain SA; Ansari J; Huddart R; Power DG; Lyons J; Wylie J; Vilarino-Varlela M; Elander NO; McMenemin R; Pickering LM; Faust G; Chauhan S; Jackson RJ
    Int J Oncol; 2017 Mar; 50(3):768-772. PubMed ID: 28098864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP.
    Makarov AA; Tsvetkov PO; Villard C; Esquieu D; Pourroy B; Fahy J; Braguer D; Peyrot V; Lafitte D
    Biochemistry; 2007 Dec; 46(51):14899-906. PubMed ID: 18052208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
    Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
    Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT
    Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group.
    Pistamaltzian N; Tzannis K; Pissanidou V; Peroukidis S; Milaki G; Karavasilis V; Mitsogiannis I; Varkarakis I; Papatsoris A; Dellis A; Adamakis I; Stravodimos K; Molyva D; Athanasiadis I; Androulakis N; Andreadis C; Kalofonos C; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamias A
    Anticancer Drugs; 2016 Jan; 27(1):48-53. PubMed ID: 26421462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.
    Gerullis H; Ecke TH; Janusch B; Arndt C; Heidari M; Oniani J; Otto T
    Anticancer Drugs; 2011 Oct; 22(9):940-3. PubMed ID: 21642839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vinflunine for the treatment of non-small cell lung cancer.
    Genova C; Alama A; Coco S; Rijavec E; Dal Bello MG; Vanni I; Biello F; Barletta G; Rossi G; Grossi F
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1447-1455. PubMed ID: 27771969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine.
    Harshman LC; Fougeray R; Choueiri TK; Schutz FA; Salhi Y; Rosenberg JE; Bellmunt J
    Br J Cancer; 2013 Nov; 109(10):2548-53. PubMed ID: 24129239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Cortes J; Perez-Garcia J; Levy C; Gómez Pardo P; Bourgeois H; Spazzapan S; Martínez-Jañez N; Chao TC; Espié M; Nabholtz JM; Gonzàlez Farré X; Beliakouski V; Román García J; Holgado E; Campone M
    Ann Oncol; 2018 Apr; 29(4):881-887. PubMed ID: 29481630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience.
    Retz M; de Geeter P; Goebell PJ; Matz U; de Schultz W; Hegele A
    BMC Cancer; 2015 Jun; 15():455. PubMed ID: 26040470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vinflunine: clinical perspectives of an emerging anticancer agent.
    Yun-San Yip A; Yuen-Yuen Ong E; Chow LW
    Expert Opin Investig Drugs; 2008 Apr; 17(4):583-91. PubMed ID: 18363522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-line therapy in bladder cancer.
    Bachner M; De Santis M
    Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.